Why is Alembic Pharma falling/rising?

As of 10-Jul, Alembic Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at 978.90, reflecting a decrease of 7.4 points or 0.75%. The stock has been on a downward trend, having lost 2.11% over the last three days, and it has underperformed against the benchmark Sensex, which has seen a minimal decline of 0.06% over the same one-week period. The stock's performance today is described as inline with the sector, but it has shown a significant drop in investor participation, with delivery volume falling by 58.6% compared to the five-day average. Additionally, while the company has a strong ability to service debt and is trading at a discount compared to its peers, it has faced challenges with a negative return of -0.60% over the past year and a concerning annual operating profit decline of 7.30% over the last five years.
In the broader market context, Alembic Pharmaceuticals' short-term performance has been notably weaker than the benchmark, with a one-week return of -2.93% compared to the Sensex's slight decline. This underperformance is compounded by negative financial results, including a significant drop in profit after tax and a high debt-equity ratio. Despite having high institutional holdings that suggest some level of confidence from larger investors, the overall sentiment appears to be cautious due to the company's poor long-term growth prospects and recent negative financial indicators.